Analystreport

Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $300.00 price target on the stock.

Oncolytics Biotech Inc. - Common Shares  (ONCY) 
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.oncolyticsbiotech.com